0001628280-24-008977.txt : 20240305
0001628280-24-008977.hdr.sgml : 20240305
20240305165416
ACCESSION NUMBER: 0001628280-24-008977
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240303
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daly Jason B.
CENTRAL INDEX KEY: 0001906486
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 24721767
MAIL ADDRESS:
STREET 1: 400 CROSSING BLVD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
wk-form4_1709675630.xml
FORM 4
X0508
4
2024-03-03
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001906486
Daly Jason B.
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
0
1
0
0
SVP, Chief Legal Officer
0
Class A Common Stock
2024-03-03
4
M
0
22645
A
37126
D
Class A Common Stock
2024-03-03
4
F
0
7166
5.47
D
29960
D
Class A Common Stock
2024-03-03
4
M
0
38226
A
68186
D
Class A Common Stock
2024-03-03
4
F
0
10864
5.47
D
57322
D
Restricted Stock Units
2024-03-03
4
M
0
22645
0
D
Class A Common Stock
22645
45290
D
Restricted Stock Units
2024-03-03
4
M
0
38226
0
D
Class A Common Stock
38226
114679
D
Restricted Stock Units
2024-03-04
4
A
0
143519
0
A
Class A Common Stock
143519
143519
D
Performance-Based Restricted Stock Units
2024-03-04
4
A
0
287038
0
A
Class A Common Stock
287038
287038
D
Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents a performance-based restricted stock unit grant of 143,519 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.
/s/ Denis Butkovic, Attorney-in-Fact
2024-03-05